NSRX — Nasus Pharma Cashflow Statement
0.000.00%
- $61.38m
- $61.38m
- 35
- 69
- 30
- 41
Annual cashflow statement for Nasus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -0.002 | -0.001 | -0.002 |
Non-Cash Items | 0 | -0 | 0 |
Discontinued Operations | |||
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 0.001 | 0 | 0 |
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Cash from Operating Activities | -0.002 | -0.002 | -0.001 |
Other Investing Cash Flow Items | -0 | — | — |
Other Investing Cash Flow | |||
Cash from Investing Activities | -0 | — | — |
Financing Cash Flow Items | -0 | 0 | -0 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 0.002 | 0.002 | 0.002 |
Foreign Exchange Effects | |||
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -0 | 0 | 0 |